Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]
News [3529]
Articles [90]
Editorials [5]
Conferences [156]
elearning [19]
Novel JAK inhibitor pacritinib proves effective for easing symptoms of...
Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA
Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )
30 May 2015
New ibrutinib combination regimen shows substantial benefits in relapsed...
Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA
New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia ( Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )
30 May 2015
Obinutuzumab doubles remission duration in patients with relapsed, indolent non...
Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma ( Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada )
30 May 2015
First-in-class targeted drug daratumumab shows promise in heavily treatment...
Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA
First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma ( Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA )
30 May 2015
Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse...
Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA
Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction ( Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA )
29 May 2015
Pembrolizumab for head and neck cancer
Dr Tanguy Seiwert - University of Chicago, Chicago, USA
Pembrolizumab for head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )
29 May 2015
Genomic marker predicts anti-PD-1 response in several cancers
Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA
Genomic marker predicts anti-PD-1 response in several cancers ( Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )
29 May 2015
Nivolumab extends survival for NSCLC
Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Nivolumab extends survival for NSCLC ( Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
29 May 2015
Promising results for nivolumab in advanced liver cancer
Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive...
Promising results for nivolumab in advanced liver cancer ( Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA )
29 May 2015
Nivolumab extends survival for patients with the most common lung cancer
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Nivolumab extends survival for patients with the most common lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
29 May 2015
Pembrolizumab shows promising activity against head and neck cancer
Dr Tanguy Seiwert - University of Chicago, Chicago, USA
Pembrolizumab shows promising activity against head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )
29 May 2015
Nivolumab shows highly promising activity in advanced liver cancer in early...
Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive...
Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial ( Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA )
29 May 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation